2019 Annual Meeting of the American Association for the Study of Liver Diseases*

Nonrandomized, prospective study showed that a formal in-person education session resulted in sustained improvement in patients’ HBV knowledge, which was associated with downstream improvements in HBV monitoring and management.

This large population-based observational study demonstrated that medical follow-up every 3-6 months associated with significantly lower HCC mortality in patients with CHB.

Large study from Hong Kong finds that the risk of developing HCC is equally low for patients with spontaneous HBsAg loss and NA-induced HBsAg clearance.

HCV is a common cause of HCC among African-born immigrants in Minnesota.

Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.

External validation supports scoring system for identifying patients with low risk of HCC following SVR.

HCV reinfection rates in British Columbia were relatively low following SVR with DAA treatment but were higher among persons who inject drugs vs the overall cohort.

Presence of advanced hepatic fibrosis, CKD, and elevated cardiac risk score increase risk of mortality in all patients with NAFLD, regardless of BMI.

Obeticholic acid 10 mg and 25 mg improved liver fibrosis, steatohepatitis, and liver biochemistry in expanded ITT population that included patients with fibrosis stages 1-3.

This small study showed that a short preemptive course of GLE/PIB + EZE given pre- and post-transplant prevented HCV transmission in all HCV-uninfected patients who received organs from HCV-infected donors.